Alzinova: Short comment on yesterday’s aducanumab news

Research Note

2021-11-18

09:19

Redeye leaves a short comment on the EMA’s negative trend vote on Biogen’s aducanumab and what it means for Alzinova.

KS

Kevin Sule

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.